#USA #Northbrook #710GO #Kalohexis #MC3R/MC4R

Kalohexis Unveils Groundbreaking Findings on Obesity Treatment

Kalohexis, a clinical-stage biotechnology firm, has made headlines with its recent publication in Nature Communications, revealing that the dual activation of the melanocortin receptors MC3R and MC4R may act as a new and effective treatment for obesity. This revelation is particularly timely as the global obesity epidemic continues to escalate, prompting increased interest in innovative therapies.

The Research Breakthrough

The study led by Dr. Daniel Marks, Kalohexis's Chief Scientific and Medical Officer, demonstrated that the dual agonist, 710GO, significantly reduces body weight and food intake among male primates suffering from obesity. The publication highlights that, compared to traditional selective approaches, this method drives superior weight loss while minimizing the side effects often associated with similar treatments.

In the study, non-human primates subjected to 710GO saw an impressive 11.7% reduction in body weight over a 13-week period. Notably, most weight loss was attributed to fat mass reduction, with minimal impact on lean mass. This sustained weight loss approach provides more hope that patients can keep off the weight once treatment ends.

Advantages Over Current Treatments

Kalohexis's publication suggests crucial enhancements over previous therapies such as GLP-1 agonists and MC4R-selective approaches. By targeting both MC3R and MC4R, this novel treatment appears to address the shortfalls of older methods effectively. Clinical testing showcases limited gastrointestinal adverse events and no significant cardiovascular issues, even when the drug was administered in higher-than-normal doses.

Moreover, when combined with semaglutide, another obesity medication, 710GO facilitated greater weight loss than either compound could achieve individually, underscoring its potential synergistic effects. This compatibility opens new doors for combination therapies which could further improve patient outcomes.

Kalohexis: A Promising Future

Formed in March 2026 from Endevica Bio, Kalohexis is positioning itself at the forefront of metabolic disease treatment, focusing on innovations within the melanocortin system. The dual agonist 710GO is part of a broader portfolio aimed at addressing several metabolic disorders, including cachexia in cancer patients with another drug, mifomelatide.

As the Phase 1 clinical trials for 710GO commence, Kalohexis aims to gather more data to support its efficacy and safety further. With a strong foundation of promising research and clinical guidance, Kalohexis could significantly reshape the landscape of obesity treatment and metabolic health management.

For continued coverage of this developing story and further updates from Kalohexis, interested readers can visit the Kalohexis website or follow them on their social media platforms. This innovative approach could mark a pivotal moment in how we combat the global obesity crisis, offering patients not just weight loss, but a healthier lifestyle in the long run.